Several billion doses of Novavax’s protein-based corona vaccine should be delivered in 2021. Now there is news about the approval
Update from Thursday, December 16, 2021, 3:15 p.m.: The European Medicines Agency (EMA) has announced that it will decide in the coming week on the approval of the corona vaccine from the US pharmaceutical company Novavax. The responsible drug committee will hold an extraordinary meeting on December 20, the EMA said on Thursday. It should be about the vaccine developed by Novavax under the name Nuvaxovid.
The US group had applied for marketing authorization for Nuvaxovid for the EU in mid-November. Novavax uses the so-called spike protein from Sars-CoV-2 for its vaccine and reproduces it en masse in insect cells. After vaccination, the human immune system uses it to generate antibodies against the protein and can thus fight off Covid 19 disease. Because the vaccine – unlike the Biontech Pfizer vaccine, for example – can be stored at refrigerator temperature, the product is also considered a beacon of hope for poorer countries.
Novavax vaccine – when will it be approved in the EU?
First report from Sunday, December 5th, 2021, 1 p.m .: Gaithersburg – Many are longingly waiting for the Covid vaccine from Novavax – because this differs from the previous vaccines and promises a high level of effectiveness. As early as 2020, Novavax managing director Stanley Erck announced that deliveries of up to two billion vaccine doses could be expected in 2021. So far, however, the approval is pending. Will that change anytime soon?
In contrast to the mRNA vaccines from Biontech and Moderna, which are currently considered the most popular, immunization with the vaccine from the Novavax company is carried out using protein particles. This means that the vaccine contains particles of the Sars-CoV-2 protein produced in the laboratory, which trigger the production of antibodies in the body.
In contrast to mRNA vaccines, which contain parts of the genetic information of the virus, vaccination with protein-based vaccines has been tried and tested for a long time – an argument with which vaccination skeptics can still be convinced of a vaccination against corona. In addition, experts rate such a vaccine as particularly effective.
Novavax Corona Vaccine: CEO Announces Emergency Authorization Application
After the CEO of Novavax in the USA had already spread hope for an early approval in 2020, he again emphasized to CNN in November 2021 that he was planning to submit an application for emergency approval of the vaccine to the American drug regulator FDA this year.
So far, Novavax’s corona vaccine is only approved in Indonesia and the Philippines. Several approval processes are currently underway, for example in Europe, Great Britain, Canada and Australia. In October there were media reports in the US that Novavax was having production problems. But Novavax boss Erck is confident that the problems have been overcome. In a Novavax announcement in response to US media reports in October, it said, “Our global supply chain is expected to reach 150 million cans per month by the end of the fourth quarter.”
Novavax: Corona vaccine – means is already being adapted against the Omikron variant
The US government has already funded the vaccine company with 1.6 billion dollars, and for some time Novavax has had a partnership with the Serum Institute of India, the world’s largest manufacturer of vaccines. Silvia Taylor, Vice President Of Global Corporate Affairs And Investor Relations at Novavax, is convinced that the company will be able to produce more than two billion vaccine doses by 2022. In addition, the company promised that the vaccine is currently being adapted to the new Omikron variant.
With the new Omikron variant, the global corona situation is getting worse. The current developments regarding the mutation in the ticker. (tt / AFP)
Transparency notice: We have revised the article in some places.
